Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04431453 · ClinicalTrials.gov registry record · Phase 2
Study of Remdesivir in Participants Below 18 Years Old With COVID-19
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT04431453 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 59 participants.
The verdict
NCT04431453, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
The goals of this clinical study are to learn more about the study drug, remdesivir, and how safe it is in participants less than 18 years old with coronavirus disease 2019 (COVID-19).
Interventions
- DRUG Remdesivir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2020-07-21 |
| Est. Completion | 2023-02-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04431453
The ClinicalTrials.gov registry entry for NCT04431453 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Remdesivir is the first listed.
NCT04431453 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04431453 about?
NCT04431453 is a clinical study titled "Study of Remdesivir in Participants Below 18 Years Old With COVID-19". The goals of this clinical study are to learn more about the study drug, remdesivir, and how safe it is in participants less than 18 years old with coronavirus disease 2019 (COVID-19).
What is the current status of trial NCT04431453?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2020-07-21. Estimated completion is 2023-02-10.
What interventions are being tested in trial NCT04431453?
The interventions under investigation include: Remdesivir (DRUG).
Who is sponsoring clinical trial NCT04431453?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.